Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of BEA 2180 via Respimat in COPD
2005-000650-79Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bea 2180 in chronic obstructive pulmonary disease (COPD) (7 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Trough FEV1 response at end of 4-week treatment period. Started Jul 2005; status: completed.
02
Drugs
bea 2180
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2005-000650-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000650-79.